Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years

MRI contrast agent can now be used to detect disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in youngest patients, including term neonates

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years

September 6, 2017 — Guerbet LLC USA announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine) for intravenous use with magnetic resonance imaging (MRI) in pediatric patients under two years old, including term neonates. The contrast agent can be used to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system (CNS).

Dotarem was previously approved for this use in patient populations over the age of two.

This supplemental indication fulfills a post marketing requirement, acknowledged when Dotarem was first registered in March 2013, to strictly comply with the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c).

The FDA's review was based on a study showing that at the standard dose (0.1 mmol/kg),1 the pharmacokinetic (PK) and safety profiles in pediatric patients under two were similar to those of older children and adults.

The clinical study enrolled 51 pediatric patients in nine centers, with ages spanning from term neonates to 23 months and with normal renal function. It evaluated 45 pediatric patients for PK profile and safety, including five subjects aged less than one month and nine subjects aged one to three months. It assessed efficacy in a subset of 28 subjects who underwent an MRI examination of brain, spine and associated tissues.

In this pediatric population the observed safety profile of Dotarem was consistent with what has been reported in older populations. In one patient, rash was reported as a moderate adverse event (AE). Serious AEs unrelated to Dotarem were reported in one out of 45 patients. Evaluation of images from contrast-enhanced MRI of the CNS supported extrapolation of CNS efficacy findings reported in adults and older children.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast medium (a kind that provides high molecular stability) available in the United States.

For more information: www.guerbet.com

Read the related article "Recent Trends and Developments in Contrast Media."
 

 

References

1. Dotarem (gadoterate meglumine) US Prescribing Information

Related Content

Mayo Clinic Installing First FDA-Approved Clinical 7T MRI
News | Magnetic Resonance Imaging (MRI) | October 20, 2017
Mayo Clinic in Rochester, Minn., will have the first clinical 7-Tesla magnetic resonance imaging (MRI) scanner in North...
Edward-Elmhurst Health Completes CR-to-DR Conversion With Carestream Systems
News | Digital Radiography (DR) | October 20, 2017
October 20, 2017 — Edward-Elmhurst Health of Naperville, Ill., has installed four Carestream DRX-Evolution Plus and D
Median Technologies Brings iBiopsy Platform to The Liver Meeting
News | Advanced Visualization | October 20, 2017
October 20, 2017 — Median Technologies announced that it will participate in The Liver Meeting, the annual meeting of
Contrast-Enhanced Ultrasound Safe and Effective Detector of Liver Cancer
News | Ultrasound Imaging | October 19, 2017
Doctors can effectively detect liver cancer with ultrasound and tiny microbubbles, according to a study announced at...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
Sonoscanner Obtains FDA Approval for U-lite EXP Portable Ultrasound
Technology | Ultrasound Imaging | October 18, 2017
Sonoscanner recently announced it received U.S. Food and Drug Administration (FDA) approval to market its new...
Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
HealthMyne QIDS 3.0 Platform Addresses Incidental Findings Workflow
Technology | PACS Accessories | October 18, 2017
October 18, 2017 — HealthMyne announced the release of QIDS (Quantitative Imaging Decision Support) 3.0 with the Inci
Carestream Introduces Wireless Tablet-Based DR Converter
Technology | Digital Radiography (DR) | October 18, 2017
October 18, 2017 — Carestream Health looks to make converting to...
Overlay Init